Acquisition of a triple quadrupole mass spectrometer for small molecule analysis

 描述（由申请人提供）：本提案的总体目标是获得资金，用于购买三重四极杆质谱仪，以取代最近退役的11.5岁的Applied Biosystems（AB）SCIEX API 3000三重四极杆LC仪器。这笔资金将用于购买AB SCIEX Triple Quad”4500系统（串联四极杆质谱仪）以及Shimadzu Nexera UHPLC色谱系统，该系统将专门用于支持NIH资助的需要定量分析的研究人员。约翰霍普金斯和中大西洋共享资源联盟机构（4个主要机构，3个次要机构）的一组研究人员已经确定，他们的研究（100%由NIH资助）依赖于只有使用所要求的仪器才能进行的分析。约翰霍普金斯大学西德尼·金梅尔综合癌症中心（JHU SKCCC）自1976年以来一直是NCI指定的综合癌症中心。JHU SKCCC分析药理学核心（JHU APC）是癌症中心的共享资源，为受资助的研究人员提供技术专业知识，并获得大型设备，用于抗癌药物和相关化合物的定量分析。JHU APC被NIH资助的赠款大量使用，用于支持在癌症患者中进行有希望的新疗法（UM 1），艾滋病恶性肿瘤（U 01），脑肿瘤（UM 1）或晚期发展（U10）的临床试验。JHU APC还支持临床前研究项目，例如，GCPII抑制剂（R 01）的临床前开发以及SPORE（P50）和中大西洋共享资源联盟（P30）的临床前项目。由于JHU APC支持抗癌药物的早期临床开发和临床前癌症相关研究，因此它是癌症中心的关键资源， 约翰霍普金斯和中大西洋共享资源联盟（MASRC）机构。这一关键资源经历了需要分析服务的基础和临床研究人员数量的快速增长。因此，现有LC/MS/MS仪器目前已满负荷使用。API 3000在使用超过11.5年后于2013年12月完全退役，因为ABSciex通过停止为该仪器提供服务和更换部件而使API 3000产品线过时。因此，JHU APC的容量大幅下降（约33%），直到合格的新质谱仪在我们的实验室中正常运行。添加新的LC/MS/MS以取代过时的LC/MS/MS将直接使NIH资助的早期临床试验和临床前项目受益。此外，它将间接受益于NIH资助的合同和研究，这些合同和研究目前没有通过在现有LC/MS/MS上腾出时间来资助。JHU APC的LC/MS/MS能力将有助于约翰霍普金斯和中大西洋共享资源联盟（MASRC）机构的长期生物医学研究目标

 DESCRIPTION (provided by applicant): The overall goal of this proposal is to acquire funds to purchase a triple quadrupole mass spectrometer to replace a recently decommissioned 11.5-year old Applied Biosystems (AB) SCIEX API3000 Triple Quad LC instrument. The funds will be used to purchase an AB SCIEX Triple Quad" 4500 system (a tandem quadrupole mass spectrometer) coupled with a Shimadzu Nexera UHPLC chromatographic system that will be dedicated to support NIH-funded investigators requiring quantitative analysis. A group of investigators at the Johns Hopkins and Mid-Atlantic Shared Resources Consortium Institutions (4 major, 3 minor) has been identified whose research (100% NIH-funded) is dependent on analyses which are only possible with the requested instrument. The Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center (JHU SKCCC) is a NCI-Designated Comprehensive Cancer Center since 1976. The JHU SKCCC Analytical Pharmacology Core (JHU APC) is a Cancer Center shared resource that provides funded investigators with technical expertise and access to large equipment for quantitative analysis of anticancer drugs and related compounds. The JHU APC is used heavily by NIH-funded grants supporting the conduct of clinical trials in cancer patients with promising new therapies (UM1), AIDS malignancies (U01), with brain tumors (UM1) or late-stage development (U10). The JHU APC also supports preclinical research projects, e.g., preclinical development of GCPII inhibitors (R01) and preclinical projects from SPOREs (P50s) and the Mid-Atlantic Shared Resource Consortium (P30s). As the JHU APC supports both early clinical development of anti-cancer drugs and pre-clinical cancer-related research, it is a critical resource for the Cancer Center and the Johns Hopkins and Mid-Atlantic Shared Resource Consortium (MASRC) Institutions. This critical resource has experienced a rapid growth in the number of basic and clinical investigators requiring analytical services. As a result, usage of the existing LC/MS/MS instrument is currently at full capacity. An API3000 was fully decommissioned in December 2013 after over 11.5 years of service since ABSciex made the API3000 product line obsolete by ceasing to provide service and replacement parts for this instrument. Therefore, the capacity of the JHU APC has decreased substantially (by ~33%) until a qualified new mass spectrometer is functionally up and running in our laboratory. The addition of a new LC/MS/MS to replace the outdated LC/MS/MS will directly benefit NIH grant-funded early clinical trial and preclinical projects. In addition, it will indirectly benefit NIH-funded contracts and studies that are not currently NIH funded by freeing time on the existing LC/MS/MS. The LC/MS/MS capability of the JHU APC will contribute to the long-range biomedical research goals of the Johns Hopkins and Mid-Atlantic Shared Resource Consortium (MASRC) Institutions